180 related articles for article (PubMed ID: 12914745)
41. [Growth hormone-receptor antagonist pegvisomant].
Herrmann BL; Strasburger CJ
Dtsch Med Wochenschr; 2004 Oct; 129(44):2356-8. PubMed ID: 15497105
[No Abstract] [Full Text] [Related]
42. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
[TBL] [Abstract][Full Text] [Related]
43. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis.
Tritos NA; Mattsson AF; Vila G; Biller BMK; Klibanski A; Valluri S; Hey-Hadavi J; Kelepouris N; Jimenez C
Eur J Endocrinol; 2020 Mar; 182(3):285-292. PubMed ID: 31917681
[TBL] [Abstract][Full Text] [Related]
44. [Pegvisomant decreases growth hormone to nothing].
Krankenpfl J; 2004; 42(1-2):16-7. PubMed ID: 15116768
[No Abstract] [Full Text] [Related]
45. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
[TBL] [Abstract][Full Text] [Related]
46. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
47. Growth hormone receptor antagonists therapy for acromegaly.
Parkinson C; Trainer PJ
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):419-30. PubMed ID: 10909433
[TBL] [Abstract][Full Text] [Related]
48. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
Drake WM; Rowles SV; Roberts ME; Fode FK; Besser GM; Monson JP; Trainer PJ
Eur J Endocrinol; 2003 Dec; 149(6):521-7. PubMed ID: 14640992
[TBL] [Abstract][Full Text] [Related]
49. Pegvisomant (Somavert) for acromegaly.
Med Lett Drugs Ther; 2003 Jul; 45(1160):55-6. PubMed ID: 12840714
[No Abstract] [Full Text] [Related]
50. Population pharmacokinetic and pharmacodynamic modeling of pegvisomant in asian and Western acromegaly patients.
Muto C; Chiba K; Suwa T
J Clin Pharmacol; 2011 Dec; 51(12):1628-43. PubMed ID: 21209237
[TBL] [Abstract][Full Text] [Related]
51. GH receptor antagonist: mechanism of action and clinical utility.
Surya SK; Barkan AL
Rev Endocr Metab Disord; 2005 Jan; 6(1):5-13. PubMed ID: 15711909
[TBL] [Abstract][Full Text] [Related]
52. The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly.
Paisley AN; Trainer PJ
Horm Res; 2004; 62 Suppl 1():83-8. PubMed ID: 15761238
[TBL] [Abstract][Full Text] [Related]
53. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly.
Bianchi A; Mazziotti G; Tilaro L; Cimino V; Veltri F; Gaetani E; Pecorini G; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2009; 12(3):196-9. PubMed ID: 19089622
[TBL] [Abstract][Full Text] [Related]
54. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
55. Experience from the Argentine Pegvisomant Observational Study: preliminary data.
García Basavilbaso N; Guitelman M; Nagelberg A; Stalldecker G; Carabelli A; Bruno O; Danilowitz K; Manavela M; Mallea Gil S; Ballarino C; Guelman R; Katz D; Fidalgo S; Leal R; Fideleff H; Servidio M; Bruera D; Librandi F; Chervin A; Vitale M; Basso A
Front Horm Res; 2010; 38():42-49. PubMed ID: 20616494
[TBL] [Abstract][Full Text] [Related]
56. USAN Council. List No.428. New names. Pegvisomant.
Clin Pharmacol Ther; 2000 Jul; 68(1):106. PubMed ID: 10991628
[No Abstract] [Full Text] [Related]
57. Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly.
Jimenez C; Ayala-Ramirez M; Liu J; Nunez R; Gagel RF
Horm Metab Res; 2011 Jan; 43(1):55-61. PubMed ID: 21104581
[TBL] [Abstract][Full Text] [Related]
58. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
[TBL] [Abstract][Full Text] [Related]
59. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial.
Madsen M; Krusenstjerna-Hafstrøm T; Møller L; Christensen B; Vendelbo MH; Pedersen SB; Frystyk J; Jessen N; Hansen TK; Stødkilde-Jørgensen H; Flyvbjerg A; Jørgensen JO
J Clin Endocrinol Metab; 2012 Apr; 97(4):1227-35. PubMed ID: 22298804
[TBL] [Abstract][Full Text] [Related]
60. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects.
Brian SR; Bidlingmaier M; Wajnrajch MP; Weinzimer SA; Inzucchi SE
J Clin Endocrinol Metab; 2007 Sep; 92(9):3374-7. PubMed ID: 17595256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
